Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Comment: PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 314

Dr John Heymach & Prof Richard Schilsky

Dr John Heymach and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a study looking at the use of PD-1 immunotherapy versus chemo alone as first line lung cancer treatment.

For more on these results, watch Dr Lopes present the data in the press conference, watch his interview with ecancer and read our news coverage here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation